What does the research show about albuterol?

Albuterol

Trials found albuterol widened the airways within minutes for about 4 hours and protected against exercise-induced narrowing. Taken alone as needed, it left twice the exacerbation rate of as-needed budesonide-formoterol. In athletes without asthma, beta-agonists did not change endurance. Heart rate rose and potassium fell after a dose, and heavy use was linked to more deaths.

Add to Bio HackChecked 2026-11-13

Status: Prescription drug in the US. The inhaler label lists treatment or prevention of bronchospasm in people aged 4 and older with reversible obstructive airway disease, and prevention of exercise-induced bronchospasm.
Also called: salbutamol, albuterol sulfate, Ventolin, Ventolin HFA, ProAir, ProAir HFA, ProAir RespiClick, ProAir Digihaler, Proventil, rescue inhaler, short-acting beta-agonist, SABA
Taken for: asthma attacks, rescue inhaler, wheezing, COPD, exercise-induced asthma, high blood potassium, athletic performance, sprint and strength

Strong several reviews agree · Moderate one review or consistent trials · Limited one or a few small studies · Untested no study in people, listed with what it rests on

Shown to help5

ModerateShown to improve lung function more than a placebo inhaler in people with asthma, starting within about 5 minutes and lasting about 4 hours in responders.
ModerateShown to protect against the drop in lung function after exercise, with about 18 percentage points less fall in FEV1 than placebo after a single dose.
ModerateShown to improve lung function slightly and daily breathlessness in stable COPD compared with placebo, and people preferred it to placebo about 9 times as often.
ModerateShown to cut hospital admission when beta-agonists were nebulized continuously rather than in separate doses in the emergency department, most in people with severe airway obstruction.
LimitedSmall studies found inhaled and nebulized beta-agonists lowered blood potassium in hyperkalemia, and adding insulin with glucose lowered it more than either alone.

Reported risks6

ModerateShown in label trials to raise throat irritation, cough and respiratory infections slightly against a placebo inhaler, with throat irritation in 10% against 7%.Very common
ModerateShown to raise heart rate by about 9 beats a minute after one dose. Over longer trials, cardiovascular events rose, mostly from a fast heart rate.How often is not known
ModerateShown to lower blood potassium by about 0.36 mmol/L after a single dose. The label calls the drop usually temporary.How often is not known
LimitedLinked to more exacerbations and deaths with more canisters a year: 11 or more canisters carried 2.35 times the risk of death of 2 or fewer.How often is not known
LimitedThe label warns albuterol can cause paradoxical bronchospasm, which may be life threatening and often occurs with the first use of a new canister. It gives no rate.How often is not known
LimitedThe label warns that beta-blockers block albuterol and may cause severe bronchospasm, diuretics may worsen low potassium, and MAOIs or tricyclics may strengthen its effects on blood vessels.How often is not known

What people take it for, and what was found

Shown to help5

Moderate

Quick relief of airway narrowing in asthma

Shown to improve lung function more than a placebo inhaler in people with asthma, starting within about 5 minutes and lasting about 4 hours in responders.

Compared with a placebo inhaler [1]

The numbers and sources

Effect: In two 12-week trials, 2 inhalations of albuterol produced greater improvement in FEV1 from before the dose than placebo. In people whose FEV1 rose at least 15% within 30 minutes, the mean time to that rise was 5.4 minutes, peak effect came at 56 minutes, and the effect lasted about 4 hours, up to 6 hours in some [1].
Population: 610 people aged 12 and older with mild to moderate asthma in two randomized double-blind trials [1].
Sources: [1]
Caveats: Label trials. Some participants also used inhaled steroids [1].

Moderate

Preventing exercise-induced airway narrowing

Shown to protect against the drop in lung function after exercise, with about 18 percentage points less fall in FEV1 than placebo after a single dose.

Compared with placebo [2][1]

The numbers and sources

Effect: A single dose of a short- or long-acting beta-agonist before exercise reduced the maximum fall in FEV1 against placebo (MD -17.67%, 95% CI -19.51% to -15.84%). Side effects did not differ from placebo [2]. In a label trial, 2 inhalations of albuterol about 30 minutes before exercise prevented exercise-induced bronchospasm more than placebo [1].
Population: 53 trials with 1,139 participants, 45 of single doses [2]; 24 adults with asthma [1].
Sources: [2], [1]
Caveats: The meta-analysis pooled short- and long-acting beta-agonists, and heterogeneity was high in children [2].

Moderate

Stable COPD

Shown to improve lung function slightly and daily breathlessness in stable COPD compared with placebo, and people preferred it to placebo about 9 times as often.

Compared with placebo [3]

The numbers and sources

Effect: Regular short-acting beta-agonists raised FEV1 by 0.14 L (95% CI 0.04 to 0.25) and FVC by 0.30 L, raised morning peak flow by 29 L/min, and improved daily breathlessness (SMD 1.33). Dropping out for treatment failure was about half as likely (RR 0.49, 95% CI 0.33 to 0.73) [3].
Population: 13 crossover trials in people with stable COPD [3].
Sources: [3]
Caveats: Crossover trials of at least a week. The review predates the long-acting bronchodilators now used for COPD [3].

Moderate

Continuous nebulized doses in a severe attack

Shown to cut hospital admission when beta-agonists were nebulized continuously rather than in separate doses in the emergency department, most in people with severe airway obstruction.

Compared with intermittent nebulized beta-agonist [5]

The numbers and sources

Effect: Continuous treatment lowered admission against intermittent treatment (RR 0.68, 95% CI 0.5 to 0.9), and more in severe obstruction (RR 0.64). FEV1 (SMD 0.3) and peak flow (SMD 0.33) improved slightly more by 2 to 3 hours. Pulse rate and blood pressure did not differ [5].
Population: 461 patients with acute asthma in 8 trials [5].
Sources: [5]
Caveats: Small trials. The review covers beta-agonists given in emergency care [5].

Limited

Lowering high blood potassium

Small studies found inhaled and nebulized beta-agonists lowered blood potassium in hyperkalemia, and adding insulin with glucose lowered it more than either alone.

Compared with control groups in small trials, which the abstract does not describe [9]

The numbers and sources

Effect: Inhaled and nebulized beta-agonists and intravenous insulin with glucose all lowered serum potassium, and nebulized beta-agonists combined with insulin and glucose lowered it more than either alone. No study reported deaths or heart rhythm problems [9].
Population: Small randomized studies of emergency treatments for hyperkalemia [9].
Sources: [9]
Caveats: Many studies were small, and the abstract gives no effect sizes. This is a hospital use, not one on the inhaler label [9].

Mixed results1

Moderate

Strength and sprint performance in people without asthma

Mixed results: beta-agonists improved strength and sprint performance by about 5% overall in people without asthma, mostly with oral, weeks-long or prohibited use. Inhaled approved doses barely differed.

Compared with placebo [11]

The numbers and sources

Effect: Overall, beta-agonists improved anaerobic performance by about 5% (SDM 0.29, 95% CI 0.16 to 0.42). The effect was 0.14 (95% CI 0.00 to 0.28) for drugs and doses approved in sport and 0.46 for prohibited ones, 0.16 for inhaled and 0.51 for oral use, and 0.20 for a single dose against 0.50 over weeks. Strength (0.35) and sprint (0.17) both improved [11].
Population: 34 randomized placebo-controlled studies with 472 participants without asthma [11].
Sources: [11]
Caveats: The authors state it is uncertain whether doses approved in sport improve performance. Results are pooled across beta-agonists [11].

Not shown to help4

Moderate

Spacer or nebulizer in an asthma attack

Not shown to change hospital admission whether a beta-agonist was given by spacer or by nebulizer. Children spent 33 minutes less in the emergency department with a spacer.

Compared with the same drug given by nebulizer [4]

The numbers and sources

Effect: Admission did not differ between spacer and nebulizer in adults (RR 0.94, 95% CI 0.61 to 1.43) or children (RR 0.71, 95% CI 0.47 to 1.08). In children, time in the emergency department was 33 minutes shorter with a spacer, pulse rose less and tremor was less likely (RR 0.64). Lung function was similar [4].
Population: 1,897 children and 729 adults with acute asthma in 39 trials [4].
Sources: [4]
Caveats: Moderate-quality evidence. The trials compared delivery methods, not the drug against placebo [4].

Moderate

Regular scheduled use against use as needed

Not shown to change lung function or major asthma exacerbations when taken on a schedule rather than as needed, though regular users needed slightly less rescue medicine.

Compared with the same drug used as needed [6]

The numbers and sources

Effect: No clinically or statistically significant differences were found in airway caliber. Regular treatment groups used 0.80 fewer rescue puffs a day and had 6.7% fewer days with symptoms. The odds of at least one major exacerbation did not differ [6].
Population: 49 trials of short-acting beta-agonists in chronic asthma [6].
Sources: [6]
Caveats: The review dates from 2003, and many trials were crossover studies [6].

Moderate

As-needed albuterol alone against as-needed budesonide-formoterol

Shown to leave about twice the asthma exacerbation rate of as-needed budesonide-formoterol in adults with mild asthma, 0.400 a year against 0.195.

Compared with as-needed budesonide-formoterol [7][8]; regular budesonide plus as-needed albuterol [7]

The numbers and sources

Effect: Over 52 weeks, the annual exacerbation rate was 0.400 on albuterol as needed and 0.195 on budesonide-formoterol as needed (relative rate 0.49, 95% CI 0.33 to 0.72). Severe exacerbations numbered 23 and 9 (RR 0.40, 95% CI 0.18 to 0.86) [7]. Across trials of a fast-acting bronchodilator alone, 109 per 1,000 had an exacerbation needing oral steroids against 52 per 1,000 on budesonide-formoterol as needed (OR 0.45, 95% CI 0.34 to 0.60) [8].
Population: 668 adults with mild asthma in an open-label trial [7]; 9,657 participants in 6 trials, mean age 36 to 43 [8].
Sources: [7], [8]
Caveats: The trial was open-label and funded in part by AstraZeneca [7]. In the pooled analysis the fast-acting comparators were terbutaline and formoterol, not albuterol [8].

Moderate

Endurance performance in people without asthma

Not shown to improve aerobic performance, time trials, time to exhaustion or VO2 max in people without asthma, whatever the beta-agonist, dose or route.

Compared with placebo [10]

The numbers and sources

Effect: Beta-agonists did not change aerobic performance against placebo (SDM 0.051, 95% CI -0.020 to 0.122), with no heterogeneity (I² 0%). The result did not depend on drug type, dose, route, treatment length or athletic level [10].
Population: 47 randomized trials with about 680 participants without asthma [10].
Sources: [10]
Caveats: The analysis pooled several beta-agonists, not albuterol alone [10].

Doses studied

The label lists 2 inhalations every 4 to 6 hours for bronchospasm, and 2 inhalations 15 to 30 minutes before exercise. Its 12-week trials used 2 inhalations 4 times daily [1]. The trial against budesonide-formoterol used albuterol 100 μg, two inhalations as needed [7].

Risks

Reported risks6

ModerateVery common

Throat irritation, cough and other common side effects

Shown in label trials to raise throat irritation, cough and respiratory infections slightly against a placebo inhaler, with throat irritation in 10% against 7%.

The numbers and sources

How common: Very common: more than 1 in 10 people.
Effect: On albuterol and a placebo inhaler, rates were throat irritation 10% and 7%, viral respiratory infection 7% and 4%, upper respiratory inflammation 5% and 2%, cough 5% and 2%, and musculoskeletal pain 5% and 4%. Fast heart rate, extra heartbeats, palpitations and dizziness were also observed [1].
Population: 202 people on albuterol and 201 on placebo, aged 12 and older, in two 12-week trials [1].
Sources: [1]
Caveats: The placebo group also used albuterol as needed for symptoms [1].

ModerateHow often is not known

Faster heart rate and heart events

Shown to raise heart rate by about 9 beats a minute after one dose. Over longer trials, cardiovascular events rose, mostly from a fast heart rate.

The numbers and sources

How common: How often is not known: the sources give no rate.
Effect: A single dose of a beta-agonist raised heart rate by 9.12 beats a minute (95% CI 5.32 to 12.92) against placebo. In trials of 3 days to 1 year, cardiovascular events rose (RR 2.54, 95% CI 1.59 to 4.05), sinus tachycardia (RR 3.06) more than all other events (RR 1.66, 95% CI 0.76 to 3.6) [12]. The label states beta-agonists can change pulse and blood pressure and have been reported to cause ECG changes including QTc prolongation [1].
Population: 13 single-dose and 20 longer trials in people with asthma or COPD [12].
Sources: [12], [1]
Caveats: The meta-analysis pooled several beta-agonists and gives relative, not absolute, rates [12].

ModerateHow often is not known

Low blood potassium

Shown to lower blood potassium by about 0.36 mmol/L after a single dose. The label calls the drop usually temporary.

The numbers and sources

How common: How often is not known: the sources give no rate.
Effect: A single dose of a beta-agonist lowered potassium by 0.36 mmol/L (95% CI 0.18 to 0.54) against placebo [12]. The label states beta-agonists may produce significant hypokalemia in some patients, usually transient and not needing supplements [1].
Population: Single-dose trials in people with asthma or COPD [12].
Sources: [12], [1]
Caveats: An average change, not a rate of clinically low potassium.

LimitedHow often is not known

Heavy use, asthma attacks and death

Linked to more exacerbations and deaths with more canisters a year: 11 or more canisters carried 2.35 times the risk of death of 2 or fewer.

The numbers and sources

How common: How often is not known: the sources give no rate.
Effect: Against 2 or fewer canisters a year, exacerbation risk was higher with 3 to 5 (HR 1.26), 6 to 10 (HR 1.44) and 11 or more (HR 1.77). Death risk was higher with 3 to 5 (HR 1.26), 6 to 10 (HR 1.67) and 11 or more (HR 2.35, 95% CI 2.02 to 2.72). 30% of patients collected 3 or more canisters a year [13]. The label states deaths have been reported with excessive use of inhaled sympathomimetics, with cardiac arrest after a severe asthma attack suspected [1].
Population: 365,324 people with asthma in Sweden followed an average of 85 months [13].
Sources: [13], [1]
Caveats: Observational. Heavy use may mark poorly controlled asthma rather than cause harm.

LimitedHow often is not known

Airways narrowing after a dose (paradoxical bronchospasm)

The label warns albuterol can cause paradoxical bronchospasm, which may be life threatening and often occurs with the first use of a new canister. It gives no rate.

The numbers and sources

How common: How often is not known: the sources give no rate.
Effect: The label states paradoxical bronchospasm can follow a dose and frequently occurs with the first use of a new canister [1].
Population: Labeling statement [1].
Sources: [1]
Caveats: No rate is given.

LimitedHow often is not known

Interactions with beta-blockers, diuretics, digoxin and some antidepressants

The label warns that beta-blockers block albuterol and may cause severe bronchospasm, diuretics may worsen low potassium, and MAOIs or tricyclics may strengthen its effects on blood vessels.

The numbers and sources

How common: How often is not known: the sources give no rate.
Effect: The label states beta-blockers block albuterol's effect in the lungs and may produce severe bronchospasm in asthma. Loop or thiazide diuretics' ECG changes and low potassium can be acutely worsened. Single doses of albuterol lowered serum digoxin by 16% to 22% in volunteers. The vascular effects of albuterol may be potentiated during or within 2 weeks of MAOIs or tricyclic antidepressants [1].
Population: Labeling statements and a volunteer study [1].
Sources: [1]
Caveats: The label gives no rate of harm.

Checked, no increase found1

Limited

Pregnancy

The label states epidemiological studies do not consistently show a risk of major birth defects or miscarriage with inhaled albuterol. Animal studies at high doses found cleft palate.

The numbers and sources

How common: How often is not known: the sources give no rate.
Effect: There are no randomized studies in pregnancy. Epidemiological studies and postmarketing case reports do not consistently demonstrate a risk of major birth defects or miscarriage. In mice and rabbits, cleft palate and delayed bone formation occurred at less than the maximum human inhaled dose. The label also notes that poorly controlled asthma raises risks such as preeclampsia and prematurity [1].
Population: Epidemiological studies and animal studies summarized in labeling [1].
Sources: [1]
Caveats: Observational human data only [1].

Claims tested and not found

That inhaled beta-agonists improve endurance in athletes without asthma. Across 47 randomized trials, aerobic performance did not differ from placebo (SDM 0.051, 95% CI -0.020 to 0.122) [10].
That regular daily albuterol worsens asthma control. Against use as needed, regular use did not change airway caliber or the odds of a major exacerbation [6].

Sources

U.S. Food and Drug Administration. VENTOLIN HFA (albuterol sulfate) inhalation aerosol, prescribing information. 2024. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d92c5d6b-ff10-4087-36a2-1cfc464cb967
Bonini M, Di Mambro C, Calderon MA, et al. Beta2-agonists for exercise-induced asthma. Cochrane Database of Systematic Reviews. 2013. https://doi.org/10.1002/14651858.CD003564.pub3
Sestini P, Renzoni E, Robinson S, et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2002. https://doi.org/10.1002/14651858.CD001495
Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database of Systematic Reviews. 2013. https://doi.org/10.1002/14651858.CD000052.pub3
Camargo CA, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database of Systematic Reviews. 2003. https://doi.org/10.1002/14651858.CD001115
Walters EH, Walters J. Inhaled short acting beta2-agonist use in chronic asthma: regular versus as needed treatment. Cochrane Database of Systematic Reviews. 2003. https://doi.org/10.1002/14651858.CD001285
Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. New England Journal of Medicine. 2019. https://doi.org/10.1056/NEJMoa1901963
Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database of Systematic Reviews. 2021. https://doi.org/10.1002/14651858.CD013518.pub2
Mahoney BA, Smith WA, Lo DS, et al. Emergency interventions for hyperkalaemia. Cochrane Database of Systematic Reviews. 2005. https://doi.org/10.1002/14651858.CD003235.pub2
Riiser A, Stensrud T, Stang J, et al. Aerobic performance among healthy (non-asthmatic) adults using beta2-agonists: a systematic review and meta-analysis of randomised controlled trials. British Journal of Sports Medicine. 2021. https://doi.org/10.1136/bjsports-2019-100984
Riiser A, Stensrud T, Stang J, et al. Can β2-agonists have an ergogenic effect on strength, sprint or power performance? Systematic review and meta-analysis of RCTs. British Journal of Sports Medicine. 2020. https://doi.org/10.1136/bjsports-2019-100708
Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004. https://doi.org/10.1378/chest.125.6.2309
Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. European Respiratory Journal. 2020. https://doi.org/10.1183/13993003.01872-2019

Everything in the library